Five-year IMvigor210 data confirm first-line atezolizumab mUC benefit
medwireNews: Long-term follow-up of the phase 2 IMvigor210 trial points to the continued benefit of first-line treatment with atezolizumab monotherapy in cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC).
Reporting the findings in a poster at the ESMO Congress 2021, Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, USA) and co-investigators highlighted the “durable responses and long-term survival” observed with the PD-L1 inhibitor in this patient population.
At a median follow-up of 70.8 months, the objective response rates following treatment with atezolizumab 1200 mg every 3 weeks remained unchanged from the previous analysis conducted in March 2016, at 23.5% for the 119 cisplatin-ineligible participants, 21.8% for the subset with low PD-L1 levels (immune cell [IC]0/1]; n=87), and 28.1% for those with high PD-L1 levels (IC2/3; n=32).
However, just over half (53.6%) of the responders in the total cohort had an ongoing response at the time of the current analysis, as did 47.4% and 66.7% of the responders in the PD-L1 low and high subgroups, respectively. The corresponding median durations of response were 59.1 months, 53.5 months, and unreached.
Median overall survival (OS) in the total cohort was 16.3 months, while it was 19.1 months in patients with low PD-L1 levels and 12.3 months in those with high PD-L1 levels. The OS rates at 60 months were 21.6%, 19.6%, and 27.0%, respectively.
“The 5-year OS rate seen in the overall all-comer population (≈22%) compares favourably with historic data, including gemcitabine/carboplatin in cisplatin-ineligible patients,” commented Rosenberg and colleagues.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group
This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany